SCHEMBL26075144

SCHEMBL26075144

CCOc1cccc(-c2ccc(-c3cc(C)c4cc(F)ccc4n3)c(P)c2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K4 O95819 1/20 0.43
▸ NR3C1 P04150 1/20 0.42
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ TDP1 Q9NUW8 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ HPGD P15428 2/20 0.40
▸ ALOX12 P18054 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ PDE10A Q9Y233 2/20 0.39
▸ RXRA P19793 1/20 0.39
▸ RXRB P28702 1/20 0.39
▸ FGFR1 P11362 1/20 0.39
▸ FGFR2 P21802 1/20 0.39
▸ FGFR3 P22607 1/20 0.39
▸ DHODH Q02127 7/20 0.39
▸ TP53 P04637 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ BRD4 O60885 1/20 0.38
▸ BRD2 P25440 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26075147 0.91 DHODH (0.45) MEN1KMT2ATDP1MAPTHPGD
SCHEMBL26075140 0.91 MEN1 (0.41) MAP4K4NR3C1MEN1KMT2ATDP1
SCHEMBL26075142 0.91 PDE10A (0.39) MAPTHPGDPDE10ADHODHTP53
SCHEMBL26075846 0.88 PTGS2 (0.40) MAP4K4NR3C1MEN1KMT2ATDP1
SCHEMBL26075167 0.86 DHODH (0.43) MAP4K4NR3C1MEN1KMT2ATDP1
SCHEMBL26075150 0.86 MEN1 (0.46) MAP4K4NR3C1MEN1KMT2ATDP1
SCHEMBL26075134 0.85 PTGS2 (0.47) MAP4K4NR3C1MEN1KMT2ATDP1
SCHEMBL26075139 0.83 PDE10A (0.42) MAPTHPGDPDE10ADHODHTP53
SCHEMBL26075172 0.83 MEN1 (0.44) MAP4K4NR3C1MEN1KMT2ATDP1
SCHEMBL26075173 0.81 SCN9A (0.42) MAPTHPGDPDE10ADHODHTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD MAP4K4 4780/4885NR3C1 4803/4885MEN1 2373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback